MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

MacroGenics Inc

Chiusa

SettoreSettore sanitario

3.47 2.66

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.37

Massimo

3.5300000000000002

Metriche Chiave

By Trading Economics

Entrata

-31M

-14M

Vendite

-32M

41M

EPS

-0.22

Margine di Profitto

-34.333

Dipendenti

293

EBITDA

-37M

-15M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+66.28% upside

Dividendi

By Dow Jones

Utili prossimi

12 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

98M

221M

Apertura precedente

0.81

Chiusura precedente

3.47

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 apr 2026, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Principali Notizie su Eventi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 apr 2026, 22:58 UTC

Utili

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Discorsi di Mercato

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Utili

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Utili

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Discorsi di Mercato

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Discorsi di Mercato

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Discorsi di Mercato

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Principali Notizie su Eventi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Discorsi di Mercato
Utili

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

66.28% in crescita

Previsioni per 12 mesi

Media 5.67 USD  66.28%

Alto 9 USD

Basso 4 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat